Introduction expanding lung. Cystic fibrosis (CF) is a multisystem disease due to
The AAV vector system is a promising vehicle for longmutations in the cystic fibrosis transmembrane conducterm expression in the neonatal period. The wild-type tance regulator (CFTR). The lung disease is characterized virus is nonpathogenic in humans, and single doses of by chronic, progressive respiratory obstruction and infec-AAV vectors have induced long-term (up to 6 months) tion. Children with CF have structurally normal lungs at human CFTR expression in both adult rabbit 3 and pribirth, but evidence of inflammation can be found very mate models, 4 as well as in cultured CF bronchial epiearly in life. 1 It is therefore likely that the optimal time thelial cells. 5 While wild-type AAV persists by sitefor transduction of functional CFTR into the pulmonary specific integration into human chromosome 19, 6 ,7 AAV epithelium of a CF patient is in the neonatal period prior vector DNA persists predominantly in an episomal to the onset of pulmonary inflammation and damage. form 8, 9 and integrates randomly in the host genome at a At birth, the human lung has yet to complete the much lower frequency than wild-type AAV. 9 This ciralveolar phase of development. This phase lasts for cumstance has the added advantage of decreasing the approximately 18 months and is characterized by a risk of insertional mutagenesis. marked expansion of lung surface area, as well as growth
In this study, we have tested the hypothesis that AAVin lung size. We have previously demonstrated transduc-CFTR administration to newborn rabbits leads to longtion and expression of a reporter gene in the large airterm persistence of human CFTR expression. Our data ways and alveolar stem cells of the newborn rabbit using indicate that vector DNA and vector-derived protein are an adeno-associated virus (AAV) reporter gene vector, detected for 6 weeks after inoculation, vector-derived AAV-LacZ. 2 For successful long-term CFTR gene transmRNA is detected for 3 weeks after inoculation, and that duction to occur in the neonatal period, the transduced these signals become undetectable by 6 months after inoculation. Considerable lung growth occurs over this interval, likely causing the dilution of transduced vector
Results
weeks after inoculation, sections from vehicle control aniThe neonatal New Zealand white rabbit has been well mals had no detectable vector DNA by in situ PCR. Figcharacterized as a model system for human lung develure 1a shows an example of a section from a control aniopment. 10 Our laboratory recently demonstrated AAVmal at 6 weeks; sections from control animals killed at 3 LacZ transduction of newborn rabbit alveoli and large days were similar. The epithelial cell nuclei were stained airways using this model. 2 In the experiments presented uniformly pink by the Nuclear Fast Red counterstain, below, AAV-CFTR was administered on day 3 of life, and while there was some morphologically distinct backtissue was harvested at 3-4 days after inoculation to ground extracellular black staining that was clearly disassess short-term CFTR gene transduction and protein tinguishable from nuclei that were both negative (stained expression, 2-6 weeks after inoculation to assess CFTR pink by counterstain) and positive (stained black by reacgene transduction and expression at the end of the tion product). All control animals (n = 1 at 3 days, n = 4 alveolar phase of development, and 6 months after inocuat 6 weeks) were negative for vector DNA by this assay. lation to assess long-term transduction and expression. A Sections from vector-inoculated animals demonstrated second group of animals received a second inoculum of the presence of vector DNA by black staining of the vector at 3 weeks of age and were studied at 6 weeks of nuclei both 3 days (data not shown, n = 1 of 1 animal, age to assess the response to repeat vector dosage. An inoculum 10 10 AAV-CFTR particles) and 6 weeks (Figures overall tabulation of animals studied at each time-point 1b and c, n = 6 of 6 animals, inocula 10 9 -10 10 particles) is presented in Table 1 .
after inoculation. Three of the six AAV-CFTR-exposed Standard assessment at each time-point included animals had received a second vector inoculation at 3 assays of vector-derived DNA, mRNA and protein, as weeks (see below). Vector DNA was not detected by in well as an assessment of the lung inflammation by hemasitu PCR 6 months after vector inoculation (n = 5 treated, toxylin and eosin (H+E) staining. To assess for the presdose range 10
5
-10 10 particles as described in Table 1 , n = ence of vector DNA we performed an in situ polymerase 1 control). chain reaction (PCR) with vector-specific primers. VectorVector DNA was readily detected throughout the pulderived mRNA was detected with either Northern analymonary epithelia at both the 3 day and 6 week timesis or, when mRNA levels were below the level of detecpoints. Tracheal staining was sometimes prominent (data tion of Northern analysis, a nested reverse transcriptase not shown), and likely reflects a more concentrated depo-PCR (RT-PCR) assay using vector-specific primers.
sition of vector in the large airways due to the delivery Human CFTR fusion protein expression was detected by method. A positive signal was readily observed in the immunocytochemical staining of fixed tissue sections more distal bronchioles in a patchy distribution (Figure using human CFTR or epitope peptide-directed antisera.
1b) and more uniformly at corner points of alveolar strucAs detailed in the Materials and methods, different contures ( Figure 1c ) in all vector-exposed animals. This disditions were used for tissue preservation prior to RNA tribution is consistent with our earlier study 2 in which preparation, in situ PCR, immunocytochemistry, or his-AAV-LacZ transduction was localized to alveolar type II tology. A single animal's lungs were too small to be divcells, with little expression observed in the distal bronchiided among the various assays, therefore, a given anioles. mal's lung tissue did not typically undergo assay by all methods. The numbers presented in the text below indi-AAV vector mRNA expression cate the total number of individual animals whose tissues CFTR protein is present in low abundance, and its mRNA were analyzed by the indicated assay at the indicated is typically indetectable by Northern analysis. In contrast, time-point. Unless specifically noted, all animals received in AAV-CFTR-treated animals, vector-derived mRNA inocula of 10 9 -10 10 vector particles at the 3 day and 2-6 was detectable by Northern analysis (Figure 2 ) up to 2 week time-points. Inocula for the 6 month time-point are weeks after vector inoculation. The expected hybridizdescribed in Table 1. ation at approximately 4.5 kb was detected by an oligonucleotide probe derived from CFTR exon 11 (shown in AAV-CFTR vector DNA transfer Figure 1 shows representative data from in situ PCR Figure 2 ) as well as an epitope tag region probe (data not shown) in an overall total of five of eight vector-treated performed on lung tissue sections with vector-specific probe, indicating that these probes were specific for vector-derived mRNA under these conditions. No animals had detectable vector-derived mRNA by Northern analysis after 3 weeks or more. This suggests a decrease in vector-derived mRNA expression over the weeks following vector inoculation.
To decrease the lower limit of detection of our assay for vector-derived mRNA, we used a nonquantitative RT-PCR technique. Oligo deoxy-thymidine-primed reverse transcription of total lung RNA (DNase treated prior to reverse transcription to degrade contaminating vector DNA) preceded a nested PCR reaction using vector-specific primers. As shown in Figure 3a , five of eight vectortreated animals had the expected approximately 1100 bp RT-PCR reaction product indicative of the presence of vector-derived mRNA 3 weeks after vector inoculation (dose range 10 5 -10 9 particles), while none of four control animals had positive RT-PCR reaction products. No PCR products were detected in the absence of reverse transcriptase, indicating the absence of contaminating vector DNA in these samples. The identity of the PCR product treated, dose range 10 5 -10 10 particles, n = 1 control) time-
The background staining observed in (a) was not associated with the points. There were some sporadic, but not reproducible, at 6 weeks (data not shown; four experiments total, each with one to two control and two to three vector-treated samples), suggesting that vector-derived mRNA might (10 9 particles) and none of three control animals. These experiments were not normalized to an internal standard, have been present at or near the lower limit of detection by this assay. These data are consistent with vectorand therefore are nonquantitative. Similar data were obtained 3 days after vector inoculation; vector-derived derived mRNA expression falling rapidly over the period of rapid lung growth between 2 and 6 weeks of age. mRNA was detected by Northern analysis in a vectorinoculated rabbit (dose 10 10 particles), and not in a control animal (data not shown). As expected, hybridization AAV-CFTR vector protein expression Immunoreactive, vector-derived CFTR fusion protein with endogenous rabbit CFTR (molecular weight approximately 6.5 kb) was not observed with either was detected in lung sections from these rabbits using staining with antiserum 169 was observed in the apical epithelia of the trachea (not shown) and medium airways ( Figure 4d ) in 11 of 11 vector-inoculated animals (dose range 10 9 -10 10 ) and in none of four control animals ( Figure 4c ). Of the 11 vector-inoculated animals examined in this assay, seven were killed 3 weeks after inoculation, and four were killed 6 weeks after the initial inoculation. An identical staining pattern was observed with antiserum 934 in one of one animals that had received 10 9 AAV-CFTR particles 1 month before death (data not shown). These observations suggest persistence of vectorderived protein expression throughout the alveolar phase of rabbit lung development.
No specific immunostaining with antiserum 169 was observed in animals studied 6 months after AAV-CFTR inoculation (n = 5 treated animals, dose range 10 5 -10 10 particles, n = 1 control animal). This observation suggests that growth over the first 6 months of age might dilute vector-derived protein expression. It is not possible to predict from these experiments when the major loss of expression occurs; we did not study intermediate timepoints. It also further suggests that antiserum 169 specifically immunostains human CFTR and does not recognize endogenous rabbit CFTR at the dilutions and conditions used in these experiments.
The persistence of vector-derived CFTR fusion protein expression correlates with the persistence of vectorderived DNA by in situ PCR. Both are present 6 weeks not shown, n = 3) or vector-exposed animals ( Figure 5a , n = 3, dose range 10 9 -10 10 particles). There was similarly no increased inflammation in vector-exposed animals at antiserum 934, a chicken anti-epitope tag peptide antiserum, and antiserum 169, a rabbit anti-human CFTR R the 2-6 week time-point when compared with controls. All animals at this time had minimal inflammatory infildomain peptide-directed antiserum. These antisera have been previously characterized in our laboratory. 3, 11 Antitrates with scattered neutrophils, eosinophils and mononuclear cells. Figure 5b and c are representative of n = 4 serum 169 will specifically immunoprecipitate human CFTR from transfected heterologous cells (Cheng SE, control animals, and Figure 5d is representative of n = 8 vector-treated animals (dose range 10 9 -10 10 particles). unpublished observations). Representative sections from the lungs of these experimental animals are shown in FigAfter 6 months, all animals with the exception of one (discussed below) had mild inflammatory changes, with ure 4. Both antiserum 934 (Figure 4a and b) and antiserum 169 (data not shown) detected immunoreactive slightly more inflammatory cells than animals killed at 2-6 weeks (data not shown). Again, there was no difference protein specifically in vector-treated animals within the first week after inoculation (three of three inoculated between the control animal (n = 1) and vector-exposed animals (n = 4, dose range 10 5 -10 9 particles). Histologic animals with positive immunostain, dose range 5 × 10 9 to 10 10 particles, none of three controls with positive sections were routinely reviewed with a pulmonary pathologist and a veterinary pathologist who were blinded to immunostain). Staining was localized to the apical airway epithelia in all positive animals, and had a similar pattern the animal's experimental status. One animal, who received 10 10 particles of AAV-CFTR for both antisera. This suggests that both antisera were recognizing the same, vector-expressed protein.
and was killed at 6 months of age, had obvious gross pathology of the right lung at the time of death, although A similar pattern of immunostaining was seen at 3-6 weeks after vector inoculation (Figure 4c and d) . Positive the animal was clinically well. Review of histologic sec-
Figure 4 Detection of AAV-CFTR-derived protein expression by immunocytochemistry. Animals were killed 3 days (a, b) and 6 weeks (c, d) after vector inoculation and lung tissue was fixed in formalin and embedded in paraffin before sectioning. Immunocytochemistry using an anti-epitope tag antiserum (934, a and b) or an anti-human CFTR R domain antiserum (169, c and d) was performed as described in Materials and methods. (a) Control animal studied 3 days after inoculation. (b) Animal that received 10 10 AAV-CFTR particles and studied 3 days after inoculation. (c) Control animal studied 6 weeks after inoculation. (d) Animal that received 10
10 AAV-CFTR particles and studied 6 weeks after inoculation. The positive staining is orange and the counterstain is green. The magnification of these photographs is the same as in Figure 1. tions from affected and unaffected areas of lung from this was readily detected by in situ PCR in four of four vectorexposed animals who had received one or two doses of animal with a veterinary pathologist revealed multiple areas of necrosis and acute and chronic inflammatory vector (Figure 6a ), but not in two of two vehicle controls (compare with Figure 1a) . Qualitatively, the distribution reaction. This was felt by the pathologists to most likely reflect abscess formation due to Pasteurella rather than a of PCR positive cells in the two vector-exposed groups was similar (compare with Figures 1b and c) . Prominent toxicity due to vector administration. We did not routinely maintain our rabbits in a Pasteurella-free environtracheal staining was sometimes observed (Figure 6b ). Like the singly dosed animals studied 6 weeks after vecment, and this animal represents our only infectious complication in 58 experimental neonatal animals. A female tor treatment, vector-derived mRNA was not reproducibly detected by RT-PCR in either animal that had member of our breeding colony of five adults similarly succumbed to a Pasteurella lung abscess approximately 9 received a second AAV-CFTR inoculation at 3 weeks of age and was killed at 6 weeks of age (data not shown). months previous to the death of the Pasteurella-infected experimental animal. At the time of this adult animal's Immunocytochemistry with antiserum 169 demonstrated staining of the bronchial epithelial surface in two of two illness, there were no vector-treated animals present in the rabbit colony. Thus, Pasteurella infection and lung animals who had received two doses of AAV-CFTR similar to that observed in singly dosed animals ( Figure 6c , abscesses occurred rarely and sporadically in our animal colony, and it is likely that they were not promoted by compare with Figure 4c and d). There was no additional inflammation detected by hematoxylin and eosin his-AAV-CFTR vectors.
tology associated with the second dose of vector in two of two animals ( Figure 6d , compare with Figure 5b , c Effect of repeat AAV-CFTR inoculation To assess the effect of a second inoculation of AAV-CFTR and d). vector on transduction, expression and inflammation, we exposed a separate group of animals to AAV-CFTR Clinical status At the time of AAV-CFTR delivery by intratracheal instil-SA306 on both day 3 and week 3 of age before death at 6 weeks of age. These animals were compared with two lation, the rabbits often had increased respiratory rates and mild retractions lasting 10-15 min before resolution. sets of controls; one set was given vehicle inocula at both 3 days and 3 weeks, while the second set was given vecThis finding was not different in control and vectorexposed animals. Control and AAV-CFTR exposed anitor on day 3 and vehicle at week 3. Again, vector DNA direct expression of a human CFTR fusion protein. All elements of vector-derived gene transduction and expression, vector DNA, mRNA, and immunoreactive protein were readily detected both a few days after vector inoculation and near the completion of the alveolar phase of lagomorph lung development, at the 3 week timepoint. Vector DNA and vector-derived protein expression can persist for at least 6 weeks after inoculation. Gene transduction and expression of the CFTR fusion protein using AAV-CFTR does not induce any additional inflammation in the rabbit lung compared with control animals, as assessed by standard histology. A second dose of AAV-CFTR did not qualitatively alter expression of the human CFTR fusion protein and did not induce an additional inflammatory response.
These experiments, as a group, indicate that AAV-CFTR gene transduction in the neonatal period is safe and efficacious through the alveolar phase of development. No significant inflammation was induced by vector inoculation, and the one rabbit who had significant pulmonary inflammation (histologic appearance of a pulmonary abscess) had an infectious illness and not an untoward reaction to AAV-CFTR.
Function of the transduced CFTR fusion protein
We were not able to assess the function of the transduced CFTR fusion protein. The neonatal rabbit has its own functional CFTR; transduction of the vector-encoded functional CFTR fusion protein 12 therefore does not induce a change of phenotype in the airway epithelia of the rabbit. Demonstration of physiologic efficacy by AAV-CFTR vectors will require experiments in an appropriate animal model, such as a transgenic CFTR knockout mouse.
Persistence of transduced vector and vector protein expression
In light of previous studies in adult rhesus macaques, where transduction and expression was present for at least 6 months (albeit at reduced levels over time) after vector administration, 4 our observation of a lack of vector persistence at 6 months might have been unexpected. There are significant differences, however, in both the means of vector delivery and the basic lung epithelial biology of the model systems in these experiments. In the previous experiments, 4 vector was delivered to a specific area of the lung by bronchoscopy. In our experiments,
Sections of formalin-fixed lung tissue from animals killed 3 days (a) and
vector was delivered by intratracheal instillation. This between the once-and twice-inoculated animals at the 6 week time-point. There are also significant differences between the epimals had no differences in weight gain over the time thelial biology of neonatal and adult lungs. The adult course of the experiment and were only distinguishable lung does not undergo epithelial expansion and by identifying tattoos that were made at the time of vecremodeling, and the epithelial turnover is relatively slow. tor inoculation.
Transduction of epithelial cells by AAV-CFTR might therefore be relatively stable over a period of months. The neonatal lung undergoes marked expansion over the Discussion alveolar phase with significant remodeling of the epithelium to provide an increased surface area for gas Summary of data These observations suggest that AAV-CFTR vector SA306
exchange. This requires significant cell division and differentiation from epithelial stem cells. The period followcan transduce cells of the rabbit bronchial epithelium and ing the alveolar phase similarly might require significant
The episomal persistence of AAV-CFTR vectors demonstrated in cell culture and animal models 8, 9 might also cell proliferation and differentiation from stem cells, as the body mass of an animal can quadruple, and lung volbe problematic for neonatal gene transduction. Rapid proliferation or differentiation might make loss of the epiume or lung surface area would be expected to increase by a similar magnitude. Successful transduction of episome more likely, whereas in the adult animal model, the slower turnover and proliferation of the respiratory thelial cells might be 'diluted' if vector is not well propagated during epithelial cell mitosis (such as a loss of an epithelium would allow longer persistence of the episome with less chance of loss during differentiation or episome during mitosis), or if the majority of the expanded pulmonary epithelia derives from 'new' differmitosis. Arguing against this hypothesis is the observation that episomes seem to persist stably over time in entiation of stem cells. In the latter circumstance, one would expect a fall in vector persistence if stem cells are IB3-1 cells transduced with AAV vectors, 8 although these cells may behave very differently to epithelial cells in not stably transduced.
Previous investigations of neonatal gene therapy in vivo.
An alternative hypothesis for the mechanism of vector rabbit models using AAV-reporter gene vectors have indicated that stem cells, in fact, might not be efficiently loss is selective killing of epithelial cells expressing the transduced human CFTR fusion protein. Our experitransduced in the neonatal period. Clara cells, the stem cells of the bronchiolar epithelium, in contrast to the surments have not addressed the potential immunogenicity of this fusion protein. While our immunocytochemistry rounding bronchial epithelial cells, did not demonstrate appreciable ␤-galactosidase activity after transduction distinguishes human and rabbit CFTR under the conditions used, the lack of additional inflammation in histowith AAV-LacZ (lacZ gene expression driven by the AAV p5 promoter). 2 It is not clear whether this result was due logic sections from vector-exposed animals argues against a significant host reaction. However, if there was to inefficient transduction of Clara cells or inefficient expression directed by the AAV p5 promoter in Clara selective elimination of vector-containing, human CFTRexpressing epithelial cells with only low-level inflamcells. Because the experimental conditions and predigestion of the in situ PCR method can disrupt identmation, our histologic sections might not have detected such subtle differences. ifying morphologic features, it was difficult to determine directly if Clara cells contained AAV-LacZ vector DNA Loss of transduced vector after the alveolar phase might not be so problematic when considering the overall in our experiments.
goal of CFTR gene transduction therapy. Having CFTR lation was quick frozen in either a liquid nitrogen or a dry ice/methanol bath prior to storage at −78°C. expressed during the alveolar phase might prevent injury to the developing bronchioles, the earliest site of lung pathology in CF. Once the alveolar phase is completed, Vector-specific in situ polymerase chain reaction An in situ PCR using vector-specific primers was perforand persistence of the transduced gene wanes, repeat inoculation might be considered. Our experiments med as previously described on paraformaldehyde-fixed tissue sections. 3 Tissue samples were prepared with an addressed this question in a limited way, in that we saw no heightened inflammatory response to or other adverse acid protease kit (Digene Diagnostics, Beltsville, MD, USA). After a hot start at 82°C for 10 min, the PCR reaceffect of repeat inoculation towards the end of the alveolar phase of development, although our means of tion was initiated by the addition of primers and Taq polymerase (Boehringer-Mannheim, Indianapolis, IN, reinoculation may have been inefficient. We did not address the question of whether this repeat inoculation USA). One round of amplification (40 cycles of 1 min at 95°C followed by 2 min at 55°C) was performed. The towards the end of the alveolar phase had any effect on the long-term persistence of vector.
primer sequences, designated Afl II, were located in (5′) the epitope tag region of SA306 (5′-AACCAACAIn summary, these data suggest that neonatal delivery of AAV-CFTR to the neonatal rabbit lung is safe and effi-CACTCTGATCG-3′) and (3′) human CFTR exon 7 (5′-TAGGGAAGCACAGATAA-3′). Deoxynucleoside cacious throughout the alveolar phase of development.
Persistence of vector appears to wane by 6 months of age triphosphates containing digoxigenin-UTP (Genius Kit, Boehringer-Mannheim) were included in the reaction after neonatal inoculation in the rabbit. This might be a result of vector dilution due to continued rapid lung according to the manufacturer's protocol and the reaction product was detected with an alkaline phosphatasegrowth during this time period or a lack of effective transduction of epithelial stem cells. Loss of episomal linked anti-digoxigenin antibody (1:500 dilution, Genius Kit; Boehringer-Mannheim), also according to the manuvector is also a potential problem. Repeat vector inoculation towards the end of the alveolar phase of developfacturer's protocol. The counterstain was Nuclear Fast Red (Digene Diagnostics). ment appears safe and might alleviate the decreasing vector persistence with further lung growth after the alveolar phase.
Preparation of RNA Total cellular RNA was prepared using either the RNAzol B reagent (Tel-Test, Friendswood, TX, USA) or the
Materials and methods
Trizol reagent (GibcoBRL, Gaithersburg, MD, USA) according to the manufacturer's protocol. These reagents AAV-CFTR vector SA306 gave equivalent preparations. Concentration was deterThe construction and characteristics of AAV-CFTR vector mined by absorption of ultraviolet light at 260 nm, and SA306 have been described in detail previously. 3, 13 purity of RNA was assessed by the ratio of absorption of Briefly, this vector encodes a functional human CFTR light at 260 nm to that at 280 nm (typical range 1.78-2.00), fusion protein 12 where an amino-terminal epitope tag (23 as well as by observing discrete 18S and 28S RNA bands random amino acids) is fused to the human CFTR cDNA by ethidium bromide-stained agarose gel electrophoresis. at Ile 119. Expression of this coding sequence is under RNA (1-10 g) was treated with 0.5 g RNase-free control of the promoter activity intrinsic to the AAV DNase at 37°C for 2 h followed by DNase denaturation inverted terminal repeat (ITR). The AAV-CFTR vector at 95°C for 3 min to remove contaminating vector DNA used in these studies was produced in 293 cells and before assay for vector-derived RNA. treated with DNase before titer determination, all as previously described. 5, 14 The titer of vector SA306 in Northern analysis these studies was approximately 10 12 DNase-resistant Twenty microgram samples of total RNA, prepared from particles/ml. 0.2 g of lung tissue using the RNAzol B reagent, were electrophoresed in formaldehyde on a 1.5% agarose gel. RNA was transferred to a ZetaProbe membrane and proAnimal procedures The protocol for use of neonatal New Zealand white rabbed with ␥-32 P-ATP-end-labeled oligonucleotides derived from CFTR exon 11 (5′-GATTCCACCTTCTCCAAGAAbits (NZWR) in these experiments was approved by the Animal Care and Use Committee of The Johns Hopkins 3′) or the epitope tag region (5′-TAGGGAAGCACAGA TAA-3′). University. A total of 58 neonatal animals were used in these experiments; data from all of these animals are presented in Table 1 . Inoculation AAV-CFTR vector RT-PCR DNase-treated RNA was reverse transcribed into cDNA SA306 was performed on the third day of life by percutaneous intratracheal instillation using a 24 g angiousing MoMLV-reverse transcriptase. Oligo deoxy-thymidine (oligo-dT, 0.25 g/ml) was annealed to RNA at 65°C catheter as described previously. 2 Control animals received a vehicle inoculation. Animals were killed at the for 3 min before a five-fold dilution into a reverse transcriptase reaction containing 50 mm Tris-Cl (pH 8.3), 75 indicated time by an intraperitoneal overdose of sodium pentobarbital. Lung tissue was perfused via the trachea mm KCl, 3 mm MgCl 2 , 10 mm DTT, 1600 U/ml placental RNase inhibitor, 0.5 mm dNTPs, and 400 U MoMLV and the right ventricle with 4% paraformaldehyde in phosphate-buffered saline (for in situ PCR) or 10% forreverse transcriptase (GibcoBRL). Control reactions omitted MoMLV reverse transcriptase. The resulting cDNA malin in phosphate-buffered saline (for histology and immunocytochemistry). Lung tissue was then removed was extracted using phenol/chloroform and precipitated with ethanol/acetate. 15 A nested PCR reaction with these and fixed by immersion overnight at 4°C before embedding in paraffin and sectioning. Lung tissue for RNA isocDNAs as templates was performed using 5 U Taq polymerase (Boehringer-Mannheim) and PCR buffer contoxylin and eosin staining. Photomicrographs were produced as described above. Histopathologic sections were taining 1.5 mm MgCl 2 (Boehringer-Mannheim). Primer concentration was 0.2 m each and deoxynucleotide reviewed with either a pulmonary pathologist or a veterinary pathologist who were blinded to the experimental concentration was 0.2 m. The first round used primers (5′) in the epitope tag region (5′-CACAAAAAACCAstatus of the samples. CACCACTC-3′) and (3′) in CFTR exon 11 (5′-GCTCGTTGACCTCCACTCAG-3′). The cDNA template
